SCHEMBL2761558

SCHEMBL2761558

COC(=O)c1c(O)c2c(OCc3ccc(C)cc3)cccc2oc1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EDNRA P25101 1/20 0.46
MAPT P10636 4/20 0.46
LMNA P02545 2/20 0.46
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NQO1 P15559 1/20 0.44
ALDH1A1 P00352 2/20 0.43
BRD4 O60885 1/20 0.42
ABCG2 Q9UNQ0 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MAOB P27338 5/20 0.41
ABCB1 P08183 1/20 0.41
MAOA P21397 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762251 0.91 BRD4 (0.47) EDNRAMAPTLMNARAB9AL3MBTL1
SCHEMBL2761617 0.91 EDNRA (0.54) EDNRAMAPTLMNARAB9AL3MBTL1
SCHEMBL2761687 0.84 EDNRA (0.45) EDNRAABCG2MAOBABCB1MAOA
SCHEMBL2761671 0.83 ABCG2 (0.44) EDNRAALDH1A1BRD4ABCG2MAOB
SCHEMBL2761672 0.83 ABCG2 (0.44) EDNRAALDH1A1BRD4ABCG2MAOB
SCHEMBL4203732 0.82 EDNRA (0.45) EDNRANQO1BRD4ABCG2MAOB
SCHEMBL27582279 0.75 CA12 (0.56) MAPTLMNARAB9ANQO1ALDH1A1
SCHEMBL2761583 0.75 EDNRA (0.48) EDNRAABCG2MAOBABCB1BCHE
SCHEMBL2761706 0.74 LMNA (0.46) LMNAL3MBTL1NQO1ALDH1A1
SCHEMBL2761670 0.74 LMNA (0.43) EDNRAMAPTLMNARAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 US disclosed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 US disclosed
WO-2009100250-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS HIF1AN, HIF1A, EGLN2 EDNRA 598/4885MAPT 4705/4885LMNA 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.